NKGen jumps on FDA's 'fast track' designation for Alzheimer's drug
12/02/2025 18:56
** Drug developer NKGen Biotech's shares NKGN.O surge 26%
to 47 cents
** Company says U.S. FDA has granted "fast track"
designation for its experimental drug, troculeucel, for the
treatment of moderate Alzheimer's disease, a neurodegenerative
disorder that causes cognitive impairment
** The FDA's "fast track" program is designed to facilitate
the development and expedite review of drug candidates that aim
to treat serious conditions and fulfill an unmet medical need
** NKGN is also developing the drug as a treatment for other
neurodegenerative disorders and a broad range of cancers
** Stock fell ~71% in the last 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
Recent news on Nkgen Biotech
See all newsBrief: Nkgen Biotech Expands Clinical Trial Site Network For Alzheimer’S Disease Program Across US
Brief: NKgen Biotech And Hekabio Enter Into Strategic Partnership
Brief: Nkgen Biotech Announces International And U.S. Expansion Of Phase 1/2A Troculeucel Alzheimer’S Trial
Brief: Nkgen Biotech Announces Administration Of First Dose Of Troculeucel To Stroke Patient Under FDA-Cleared Compassionate Use Program
Brief: NKGen Biotech Announces Administration Of First Dose Of Troculeucel To Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program